Multiple Myeloma Hub

What Multiple Myeloma Hub does

The Multiple Myeloma Hub is an independent medical education platform that delivers expert-curated clinical content to oncologists, hematologists, and other healthcare professionals treating multiple myeloma. Founded in 2017 and operated by Scientific Education Support (SES), the platform serves as a centralized resource covering disease subtypes (newly diagnosed, relapsed/refractory, smoldering MM), therapeutic modalities (antibody therapy, CAR T-cell therapy, proteasome inhibitors, immune modulators, cereblon-targeting agents), clinical trial data, drug approvals, and treatment guidelines. Content governance is provided by an expert steering committee of internationally recognized key opinion leaders including María-Victoria Mateos, Sagar Lonial, Paul Richardson, Bruno Paiva, and Elena Zamagni, with editorial independence maintained from sponsors.

The platform's product surface comprises a central website delivering medical information articles, a clinical trials database, a types and therapeutics directory, drug update bulletins, expert video interviews, symposium series, steering committee meeting summaries, and live congress coverage of major hematology and oncology conferences (EHA, ASCO, ASH, IMS, EBMT, ESH, EMN). A personalized account feature ("My MM Hub") allows HCPs to bookmark content, configure interest-based alerts, and view recommended content. The platform is gated to verified HCPs, with patients and carers referred to the International Myeloma Foundation and HealthTree. Underlying technology is a web-based publishing platform with third-party machine translation provided by Google; no proprietary AI or ML capabilities are disclosed.

Revenue is generated exclusively through multi-tiered pharmaceutical company sponsorship, with Gold-tier support from Pfizer and GSK, Silver from Bristol Myers Squibb and Johnson & Johnson Innovative Medicine, Bronze from Roche and Legend Biotech, and Contributor from Caribou Biosciences, plus minor targeted funding from Kite (Gilead). A supplementary Stripe-based HCP contribution system has been introduced to diversify income. Sponsors are explicitly barred from influencing content. The platform operates as a subsidiary of the broader SES network of disease-specific oncology hubs, with no separate legal entity status identified and no disclosed revenue or headcount metrics beyond the 11–50 employee range.

Name

Multiple Myeloma Hub

Legal name

Multiple Myeloma Hub

Website

https://multiplemyelomahub.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Multiple Myeloma Hub is an independent medical education platform serving oncologists and hematologists with expert-curated content on multiple myeloma treatments, clinical trials, and congress coverage, funded by multi-tiered pharmaceutical sponsorships and operated by Scientific Education Support.

Ownership category

akta.pro rank

Headquarters

HQ city

Surrey

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations, Others

Revenue model

1. Pharmaceutical sponsorship: The Multiple Myeloma Hub is funded through multi-tiered pharmaceutical company sponsorships. Funders include Bristol Myers Squibb (Silver), GSK (Gold), Johnson & Johnson Innovative Medicine (Silver), Legend Biotech (Bronze), Pfizer (Gold), Roche (Bronze), and Caribou Biosciences (Contributor). Funders have no direct influence on content, which is developed independently by SES in collaboration with the steering committee.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

The Multiple Myeloma Hub is an open-access online medical education platform that provides expert-curated content to healthcare professionals specializing in multiple myeloma. It delivers clinical trial data, drug updates, congress coverage, expert opinions, and steering committee-led educational content. The platform is funded by pharmaceutical sponsorships and is freely accessible to verified HCPs.

Product overview

The Multiple Myeloma Hub is an independent medical education platform for healthcare professionals, providing expert-curated content across multiple myeloma disease states and treatments. The platform serves as a centralized resource offering steering committee meetings, symposium series, congress coverage (EHA, ASCO, ASH, IMS, EBMT), drug updates, expert opinions, clinical trial information, and a comprehensive types and therapeutics directory. The core platform integrates these components to deliver continuous medical education and clinical updates to hematology and oncology professionals.

Differentiator

Problem solved

Functional benefit

Brands

• My Multiple Myeloma Hub: A personalized account feature allowing healthcare professionals to bookmark content, receive alerts for new content in their areas of interest, and view recommended content.

Products and services

• Multiple Myeloma Hub Platform An independent medical education platform providing expert-curated content for healthcare professionals on multiple myeloma, including clinical information, trial data, expert opinions, and drug updates. The platform offers personalized accounts for bookmarking content, receiving alerts, and accessing recommended content based on areas of interest.
• Steering Committee Meetings
• Symposium Series Virtual and in-person symposiums covering topics such as BCMA-directed therapies, treatment toxicities, and real-world clinical experience integration.
• Congress Coverage Live and post-congress coverage from major hematology and oncology conferences including EHA, ASCO, ASH, IMS, EBMT, and others.
• Drug Updates Regulatory updates on drug approvals, designations, and clinical trial results for multiple myeloma treatments.
• Clinical Trials Database Comprehensive database of clinical trials related to multiple myeloma with detailed trial information and references.

Named customers9 records

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Scientific Education Support (SES)coreStrategic or Co-development PartnerThe Multiple Myeloma Hub is developed and managed by Scientific Education Support (SES), an independent medical education provider. SES develops all content in collaboration with expert steering committees, maintaining editorial independence from funders.
• EHA-EBMT CAR T-Cell MeetingcoreStrategic or Co-development PartnerCollaboration with European Hematology Association and European Society for Blood and Marrow Transplantation for CAR T-cell therapy content and congress coverage.
• International Myeloma FoundationminorStrategic or Co-development PartnerPatient referral partnership for directing patients and carers to appropriate resources. Healthcare professionals are directed to the Multiple Myeloma Hub while patients are referred to IMF and HealthTree.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Direct peers

• PRIME Education: Accredited CME provider focused on oncology, hematology, and specialty therapeutics with pharma-funded educational programs for HCPs. Directly comparable in pharma-grant-funded HCP medical education model, including KOL-led content and congress coverage.
• Clinical Care Options (CCO): Independent medical education company providing CME-certified oncology and hematology programming funded through pharma grants. Comparable in business model, oncology/HCP audience, and reliance on multi-sponsor pharma grant funding.
• Targeted Oncology: HCP-focused oncology media brand providing clinical news, conference coverage, KOL commentary, and CME content for community and academic oncologists. Comparable in pharma-supported independent HCP media model within oncology.
• OncLive: Leading US-based oncology HCP media and education platform offering peer-reviewed commentary, congress coverage, expert interviews, and CME programming for practicing oncologists. Directly comparable in serving the same oncology HCP audience with pharma-sponsored independent content.
• MDS Hub: Another SES-operated disease-specific hub for myelodysplastic syndromes. Direct comparable on operating model (steering committee governance, multi-tier pharma sponsorship, congress coverage, free HCP access) within the adjacent hematologic malignancy space.
• VJHemOnc: Video Journal of Hematology and Oncology — open-access HCP platform providing expert video interviews, congress highlights, and clinical commentary across hematologic malignancies including multiple myeloma. Comparable in free HCP access, KOL-driven video content, and pharma-supported distribution.
• Lymphoma Hub: Sister hub operated by Scientific Education Support with the same business model (KOL-governed, pharma-sponsored, free HCP-access). Closest possible direct comparable — same parent, same sponsorship tiers, same congress coverage model — applied to a different hematologic malignancy.

Broad incumbents

• Medscape Education: WebMD-owned CME platform offering accredited medical education across all therapeutic areas, including hematology/oncology. Comparable in pharma-funded HCP CME delivery but much broader in scope and a much larger incumbent.
• ASH (American Society of Hematology): Premier hematology professional society producing the ASH annual meeting, peer-reviewed journals (Blood), and accredited CME programs. Comparable as a credible HCP education destination in hematology, but at far greater scale and as a society rather than a sponsored media platform.
• International Myeloma Society (IMS): Global medical society dedicated to myeloma with educational programming, congresses (the IMS annual meeting), and guidelines. Comparable in serving the same MM-treating HCP audience, but operates on a non-profit society model rather than pharma sponsorship.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/MM_Hub

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multiple Myeloma Hub